Iftikhar Kullo, MD
Cardiovascular Disease · Milwaukee, WINPI 1104890581
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by Fukuda Denshi Co., Ltd. at 54.8% of the total. Reporting peaked in 2019 at $3,512 and has fallen 53.1% since, to $1,647 in 2025.
Across 10 payments — averaging $1121.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fukuda Denshi Co., Ltd.$6K
- Roche Diabetes Care GmbH$4K
- Kaneka Medical America LLC$2K
- Amgen$56
- Regeneron Healthcare Solutions, Inc.$12
Across 4 payments — averaging $74,914 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$300K
What the payments were for
- Consulting fees$5,00045%
- Speaking & faculty fees$3,00027%
- Travel & lodging$3,00027%
- Food & beverage$2022%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fukuda Denshi Co., Ltd.(2 entities) | 6 | $6,147 |
| Roche Diabetes Care GmbH | 1 | $3,500 |
| Kaneka Medical America LLC | 1 | $1,500 |
| Amgen | 1 | $56 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,215 in reported general payments places this provider in the 85th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Repatha SureclickEvolocumab | 98 | $71,112 |
| Praluent PenAlirocumab | 28 | $26,159 |
| Ezetimibe | 45 | $976 |
| Rosuvastatin Calcium | 19 | $240 |
| Losartan Potassium | 16 | $156 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Milwaukee
- Lee BibloMilwaukee$280K
- David GrambowMilwaukee$267K
- Eric RobertsMilwaukee$131K
- Renuka JainMilwaukee$131K
- Evgenia RaichlinMilwaukee$73K
- Prakash ShahMilwaukee$51K
- Sisir SiddamsettiMilwaukee$44K
- Manmeet SinghMilwaukee$39K
- Jordan SwisherMilwaukee$36K
- Christian BreburdaMilwaukee$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.